Second-generation non-nucleosidic reverse transcriptase inhibitor HBY097 and HIV-1 viral load

The data suggest that HBY097 and related compounds are promising second-generation non-nucleoside inhibitors of HIV-1 reverse transcriptases, which could be included in first-line combination therapies.

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 1997-05, Vol.349 (9064), p.1517-1517
Main Authors: Rübsamen-Waigmann, Helga, Huguenel, Edward, Paessens, Arno, Kleim, Jörg-Peter, Wainberg, Mark A, Shah, Anita
Format: Article
Language:English
Subjects:
Acquired Immunodeficiency Syndrome - drug therapy
AIDS/HIV
Anti-HIV Agents - administration & dosage
Anti-HIV Agents - therapeutic use
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Antiviral Agents - administration & dosage
Antiviral Agents - therapeutic use
Biological and medical sciences
Cohort Studies
Double-Blind Method
Drug Combinations
Drug Resistance, Microbial - genetics
Drug therapy
HIV
HIV Infections - drug therapy
HIV-1 - drug effects
HIV-1 - genetics
Human immunodeficiency virus
Humans
Medical research
Medical sciences
Mutation - genetics
Pharmacology. Drug treatments
Placebos
Quinoxalines
Reverse Transcriptase Inhibitors - administration & dosage
Reverse Transcriptase Inhibitors - therapeutic use
Viral Load
Viremia - virology
Virus Replication - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The data suggest that HBY097 and related compounds are promising second-generation non-nucleoside inhibitors of HIV-1 reverse transcriptases, which could be included in first-line combination therapies.
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(97)24021-3